Mount Sinai School of Medicine  
Institutional Biosafety Committee

September 17, 2009

Members Present: Drs. Wetmur, Daefler, Moline, Simon, TenOever; Ms. Erlitz (by teleconference); Mr. Hauck, Ms. Meseck.

Also Present: Drs. Basler, Shabman; Mr. Maglione, Ms. Schneier.

1) Approval of Minutes
   a. Upon motion duly made and seconded, the minutes of the July 22nd meeting were unanimously approved.

2) Recertification
   a. Mount Sinai has received recertification through 2012 as an EFP facility with ABSL-3N status.

3) GCO #0258-7593 (Christopher Basler) Isolation of Human Monoclonal Antibodies from Individuals with the Vaccine Strain of Venezuelan Equine Encephalitis Virus.
   a. Drs. Basler and Shabman outlined the parameters of the protocol including the advantages of using Sinbus over NDV for better generation of virus in mice.
   b. Project 1 will focus on constructing a chimeric SINV/VEEV alpha-virus to find potential vaccines.
   c. Project 2 will focus on incorporation of single Ebola and Nipah genes into the SINV cDNA clone.
   d. Upon motion duly made and seconded, this project was approved for handling at BSL2.

4) Other Business
   a. Following CDC recommendations, the Standard Operating Procedures (SOP) manual has been divided into more easily accessed sections by topic. Sections of particular interest to the CDC are Biosafety and Incident Reporting. Researchers will be asked to review the manual and will have their comprehension tested.
   b. An adverse event was reported on August 18th related to one of our ongoing protocols. The incident is not suspected to be related to a vector.